胰高血糖素样肽-1类似物药物的研究进展  

Latest Progress in the Drug Development of Glucagon-Like Peptide 1 Analogues

作　　者：赵琳琳[1] 黄昆[1] 

机构地区：[1]华中科技大学同济药学院,武汉430030

出　　处：《中国现代应用药学》2010年第1期16-20,共5页Chinese Journal of Modern Applied Pharmacy

基　　金：国家自然科学基金(No30801445;No30970607);教育部博士点基金(200804871111);武汉市创新人才开发基金重大创新专项项目

摘　　要：目的介绍胰高血糖素样肽-1(GLP-1)及其类似物药物在2型糖尿病治疗中的应用。方法通过归纳总结近年来国内外相关文献,介绍了GLP-1的序列结构及其生理功能,并对其类似物药物(如Exendin-4,Liraglutide等)的临床应用或研发进展,以及它们目前在临床应用上的缺陷及相应的修饰或改造途径进行了阐述。结果与结论与现有药物比较,GLP-1及其类似物药物对2型糖尿病有着显著的疗效,在糖尿病治疗领域有广泛的应用前景。OBJECTIVE To introduce the clinical applications of GLP-1 and its analogues in type 2 diabetes.METHODS The latest research reports on the structural property and physiological functions of GLP-1 were summarized,as well as the clinical research and recent progress of clinically used GLP-1 analogues（Exendin-4 and Liraglutide,etc）.Obstacles associated with their clinical usages and the remedy modification approaches were also described.RESULTS AND CONCLUTION Compared with the other clinical medicines,GLP-1 and its analogues have been proven to have greater therapeutic potential in treating type 2 diabetes.

关 键 词：2型糖尿病 胰高血糖素样肽-1 EXENDIN-4 LIRAGLUTIDE 

分 类 号：R917.796[医药卫生—药物分析学]